GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT01299012

Completed

Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus

Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus, a Retrospective Chart Review

Lead sponsor

University at Buffalo

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Type 1 diabetes

Key I/E criterion

—

Primary endpoint

•Improved Blood Glucose comtrol in Type 1 Diabetes Patients with Liraglutide

Identifiers

Registered as

NCT IDNCT01299012

Org study ID1954

Timeline

Milestones

Study first posted2011-02-18estimated

Last update posted2017-02-09estimated

Study start2010-10 (month precision)

Primary completion2013-02actual (month precision)

Study completion2013-06actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 1 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersNot accepted

Sampling methodProbability sample

Study population text

Type 1 Diabetes Mellitus

Inclusion criteria

•Type 1 Diabetes Mellitus

Exclusion criteria

•Type 2 Diabetes Mellitus

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

1 endpoint

Primary/protocol endpoint/low confidence

Improved Blood Glucose comtrol in Type 1 Diabetes Patients with Liraglutide

Time frame:20 weeks

descriptive, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.